Amrovan Plus Tablet 5/160/5 mg
Amlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
Samchundang Pharmaceutical Co., Ltd.
MFDS item code 202106220 · Approved 2021.08.27
Treatment of hypertension, improvement of dyslipidemia, and suppression of atherosclerosis progression and cardiovascular risk
This medication is used to control blood pressure in patients with essential hypertension using a combination of amlodipine and valsartan, and to improve hypercholesterolemia and dyslipidemia with the addition of rosuvastatin. Amlodipine and valsartan are effective for hypertensive patients whose blood pressure is not adequately controlled. Rosuvastatin helps to lower lipid levels in patients with hypercholesterolemia and familial hypercholesterolemia that are not managed by diet. Furthermore, rosuvastatin delays the progression of atherosclerosis, reduces the risk of cardiovascular diseases, and decreases the likelihood of stroke and myocardial infarction. This medication is used to improve cardiovascular health and to reduce overall cardiovascular risk by controlling both blood pressure and lipid levels.
Take 1 tablet of this medicine once daily with water. It is recommended that it be taken at the same time each day, if possible (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate products may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the doses of the individual components (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher). Do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance below 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan must not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout treatment. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. Most patients are controlled with a maintenance dose of 10 milligrams once daily. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams daily. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnant. People with allergies to any ingredients in this medication or similar medications, as well as pregnant or nursing women, and patients with severe liver or kidney impairment should not use this medication. Patients with low sodium or fluid levels in the body should improve their condition before taking this medication, and if symptoms of low blood pressure occur during treatment, they should lie down immediately and seek medical attention if necessary. Patients with high potassium levels or who are taking medications that may increase potassium levels should frequently monitor their potassium levels and exercise caution. Patients with issues in kidney blood vessels or those who have received a kidney transplant, as well as those with a history of angioedema, require special observation when using this medication. Patients who have experienced heart failure or myocardial infarction should carefully monitor their condition, including kidney function, while on this medication. Acute myocardial infarction patients should be cautious as symptoms may worsen with this medication. Some ingredients in this medication can cause muscle-related side effects, such as myalgia or myopathy, and rarely rhabdomyolysis, so any abnormal muscle symptoms should be reported to healthcare providers immediately. Dizziness or fatigue may occur when driving or operating machinery, so caution is advised. This medication may affect liver and kidney functions, so regular liver and kidney function tests are recommended. There may be interactions with other medications, so if any other medications are being taken, it is essential to inform healthcare providers, especially when taken with specific antifungal agents, antibiotics, immunosuppressants, or fibrates. This medication should not be used during pregnancy or while nursing, and women planning to become pregnant should use appropriate contraception. Safety and efficacy have not been established in children under 18 years of age, so it is not recommended. Elderly patients may be more sensitive to the medication, so it is advised to start at a lower dose and monitor their condition during administration. Overdose can lead to severe hypotension or shock, so immediate hospital attention is required for appropriate treatment.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container as it may be sensitive to air or moisture. Additionally, it should be kept at room temperature between 1 to 30 degrees Celsius, avoiding extremely hot or cold environments.
Pale yellow-pink oval film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
Samchundang Pharmaceutical Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
Valsartan 80mg · Amlodipine Besylate 6.94mg +1 more
Tablet · Prescription medication · Combination
Kyungdong Pharm Co., Ltd.
Valsartan 160mg · Amlodipine Besylate 6.94mg +1 more
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
Valsartan 160mg · Amlodipine Besylate 13.87mg +1 more
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.